Category: Peptide Q&A

Can MOTS-c enhance recovery from ischemia-reperfusion injury in the heart or brain, and what is the evidence for this?

Can MOTS-c mitigate age-related cognitive decline, and what mechanisms underlie its potential in preserving brain mitochondrial function?

How does MOTS-c influence lipid metabolism, including fatty acid oxidation and adipocyte differentiation?

What is the impact of MOTS-c on brown adipose tissue activation and thermogenesis in rodent models?

What are the optimal dosing regimens (dose, frequency, duration) for MOTS-c in preclinical models, and how do they translate to human trials?

Are there differences in efficacy between oral, subcutaneous, or intravenous administration of MOTS-c, and what is the pharmacokinetic profile?

What are the long-term safety and toxicity profiles of MOTS-c in animal models, and are there any known side effects in human trials?

What is the molecular mechanism by which MOTS-c enhances insulin sensitivity and regulates glucose metabolism in skeletal muscle and adipose tissue?

Does MOTS-c interfere with endogenous peptide signaling pathways, and could chronic use lead to receptor desensitization?

How does MOTS-c interact with mitochondrial pathways to modulate cellular energy homeostasis and reduce oxidative stress?